BORRBangladesh Open Research Repository
SearchSubmitAboutContact
BORRResearch for a Better Bangladesh.
AboutSubmit PaperContactTermsPolicyGitHub

© 2026 Bangladesh Open Research Repository.

Filters

Sort By

Sort by relevanceSort by dateSort by citations
Year Range
to

Results for “"Mamun Al‐Mahtab"”

16+ results

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014

Verified

Shiv Kumar Sarin, Chandan Kumar Kedarisetty, Zaigham Abbas, Deepak Amarapurkar et al.

Journal: Hepatology InternationalYear: 2014Citations: 1496

The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. Due to the rapid advancements in the knowledge and available information, a consortium of members from co...

Health SciencesMedicineHepatologyOpen Access
Read Source

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Verified

Shiv Kumar Sarin, Ashok Choudhury, Manoj K. Sharma, Rakhi Maiwall et al.

Journal: Hepatology InternationalYear: 2019Citations: 882

The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. With international groups volunteering to join, the “APASL ACLF Research Consortium (AARC)” was formed in...

Health SciencesMedicineHepatologyOpen Access
Read Source

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Verified

Shiv Kumar Sarin, Manoj Kumar, Mohammed Eslam, Jacob George et al.

Journal: ˜The œLancet. Gastroenterology & hepatologyYear: 2019Citations: 522

The Asia-Pacific region is home to more than half of the global population and accounted for 62·6% of global deaths due to liver diseases in 2015. 54·3% of global deaths due to cirrhosis, 72·7% of global deaths due to hepatocellular carcinoma, and more than two-thirds of the global burden of acute v...

Health SciencesMedicineEpidemiologyOpen Access
Read Source

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Verified

Shiv Kumar Sarin, Ashok Choudhury, George Lau, Ming‐Hua Zheng et al.

Journal: Hepatology InternationalYear: 2020Citations: 295

Background and aims COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirr...

Health SciencesMedicineInfectious DiseasesOpen Access
Read Source

APASL consensus statements and recommendation on treatment of hepatitis C

Verified

Masao Omata, Tatsuo Kanda, Lai Wei, Ming‐Lung Yu et al.

Journal: Hepatology InternationalYear: 2016Citations: 223

The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL consensus statements and recommendation on management of hepatitis C" in March, 2015, in order to revise "APASL consensus statements and management algorithms for hepatitis C virus ...

Health SciencesMedicineHepatologyOpen Access
Read Source

An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Verified

Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, Virend K. Somers et al.

Journal: Hepatology InternationalYear: 2023Citations: 182

Background Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25–30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfu...

Health SciencesMedicineEpidemiologyOpen Access
Read Source

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

Verified

Mamun Al‐Mahtab, Michel Bazinet, Andrew Vaillant

Journal: PLoS ONEYear: 2016Citations: 176

UNLABELLED: Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from infected hepatocytes and that this effect may have clinical benefit. NAP treatment, was evaluated in two clinical studies in patients...

Health SciencesMedicineEpidemiologyOpen Access
Read Source

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Verified

Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, Vincent Wai‐Sun Wong et al.

Journal: Hepatology InternationalYear: 2025Citations: 123

Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused ...

Health SciencesMedicineEpidemiologyOpen Access
Read Source

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation

Verified

Tatsuo Kanda, George Lau, Lai Wei, Mitsuhiko Moriyama et al.

Journal: Hepatology InternationalYear: 2019Citations: 112

In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of hepatitis B virus (HBV) in patients with co-infection w...

Health SciencesMedicineHepatologyOpen Access
Read Source

A Review of Medicinal Plants with Antiviral Activity Available in Bangladesh and Mechanistic Insight Into Their Bioactive Metabolites on SARS-CoV-2, HIV and HBV

Verified

Sitesh Chandra Bachar, Kishor Mazumder, Ritesh Bachar, Asma Aktar et al.

Journal: Frontiers in PharmacologyYear: 2021Citations: 107

Currently, viral infection is the most serious health issue which causing unexpected higher rate of death globally. Many viruses are not yet curable, such as corona virus-2 (SARS-CoV-2), human immunodeficiency virus (HIV), hepatitis virus, human papilloma virus and so others. Furthermore, the toxici...

Health SciencesMedicineComplementary and alternative medicineOpen Access
Read Source

Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets

Verified

Barbara Stefañska, David Cheishvili, Matthew Suderman, Ani Arakelian et al.

Journal: Clinical Cancer ResearchYear: 2014Citations: 107

PURPOSE: We utilized whole-genome mapping of promoters that are activated by DNA hypomethylation in hepatocellular carcinoma (HCC) clinical samples to shortlist novel targets for anticancer therapeutics. We provide a proof of principle of this approach by testing six genes short-listed in our screen...

Life SciencesBiochemistry, Genetics and Molecular BiologyMolecular BiologyOpen Access
Read Source

Epidemiology of hepatitis B virus in Bangladeshi general population.

Verified

Mamun-Al­ Mahtab, Salimur Rahman, Md. Fazal Karim, Mobin Khan et al.

Journal: PubMedYear: 2008Citations: 106

BACKGROUND: Hepatitis B virus (HBV) is encountered sporadically the year round in Bangladesh. It results in a wide range of liver diseases, with asymptomatic acute hepatitis at one end to hepatocellular carcinoma (HCC) at the other end of the spectrum. METHODS: All 1018 individuals of different age ...

Health SciencesMedicineEpidemiology
Read Source

Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments

Verified

Suzanne Wait, Emily Kell, Saeed Hamid, David Handojo Muljono et al.

Journal: ˜The œLancet. Gastroenterology & hepatologyYear: 2016Citations: 96

In 2015, the Coalition to Eradicate Viral Hepatitis in Asia Pacific gathered leading hepatitis experts from Bangladesh, India, Indonesia, Malaysia, Pakistan, the Philippines, and Thailand to discuss common challenges to the burden posed by hepatitis B virus (HBV) and hepatitis C virus (HCV), to lear...

Health SciencesMedicineEpidemiology
Read Source

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

Verified

Masao Omata, Tatsuo Kanda, Lai Wei, Ming‐Lung Yu et al.

Journal: Hepatology InternationalYear: 2016Citations: 95

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection...

Health SciencesMedicineHepatologyOpen Access
Read Source

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)

Verified

Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar, Julio Aguilar, Gerardo Guillén et al.

Journal: PLoS ONEYear: 2018Citations: 92

CONTEXT: Current drugs for chronic hepatitis B therapy have a poor efficacy in terms of post-treatment sustained viral suppression and generate important side effects during and after therapy. Therapeutic vaccination with HBV antigens is an attractive alternative to test. OBJECTIVE: Evaluating the e...

Health SciencesMedicineEpidemiologyOpen Access
Read Source
PreviousPage 1 of 2+Next